Long-term Efficacy of Dupilumab Versus Tezepelumab in Asthma: A Matching-Adjusted Indirect Comparison

The Journal of Allergy and Clinical Immunology In Practice 2026 Open access

Read full text
Authors: Kenneth R. Chapman, Nick Freemantle, Patricia Guyot, Olivier Ledanois, MENA SOLIMAN, Zhixiao Wang, Yingxin Xu, Shaun Abeysinghe, Wei-Han Cheng
DOI: 10.1016/j.jaip.2026.02.015
Cited by: 2
References: 22

Abstract

BACKGROUND: Dupilumab is approved for moderate-to-severe asthma with an eosinophilic phenotype in the United States and for severe asthma with type 2 inflammation in ex-US countries. Tezepelumab is globally approved for severe asthma. However, their long-term relative efficacy is unknown. OBJECTIVE: To estimate the long-term relative efficacy of dupilumab versus tezepelumab using an unanchored matching-adjusted indirect comparison. METHODS: ) (baseline of RCTs to week 100/104). Sensitivity analysis (SA) explored key characteristics from the primary analysis. RESULTS: (MD: -0.064L, 95% CI: -0.132; 0.005, P = .07), with a significantly higher CFB in SA (MD: -0.153L; 95% CI: -0.207; -0.099, P < .0001). CONCLUSION: In the matched cohort, long-term dupilumab treatment resulted in a lower AER of all asthma exacerbations relative to tezepelumab, with lung function improvements observed in SA.

Fields of Study & Subjects

Asthma and respiratory diseases Dermatology and Skin Diseases Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
The Journal of Allergy and Clinical Immunology In Practice
Publisher
Elsevier BV
Volume
14
Issue
5
Pages
1133–1141.e3
Publication date
24 February 2026
Language
EN